Lannett Co. Rating Lowered to Neutral at Zacks (LCI)
Lannett Co. (NYSE:LCI) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued on Monday, AR Network reports. They currently have a $37.80 price objective on the stock. Zacks‘ target price would indicate a potential upside of 5.68% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Roth Capital raised their price target on shares of Lannett Co. to $34.00 in a research note to investors on Friday, November 15th. Separately, analysts at Oppenheimer upgraded shares of Lannett Co. from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, October 25th. They now have a $29.00 price target on the stock. Finally, analysts at Bank of America Corp. initiated coverage on shares of Lannett Co. in a research note to investors on Friday, October 25th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $29.70.
Shares of Lannett Co. (NYSE:LCI) traded down 0.61% during mid-day trading on Monday, hitting $35.77. The stock had a trading volume of 291,174 shares. Lannett Co. has a 52 week low of $5.49 and a 52 week high of $36.59. The stock’s 50-day moving average is $31.53 and its 200-day moving average is $20.92. The company has a market cap of $1.244 billion and a price-to-earnings ratio of 235.23.
Lannett Co. (NYSE:LCI) last released its earnings data on Thursday, November 7th. The company reported $0.22 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.13 by $0.09. The company had revenue of $45.82 million for the quarter, compared to the consensus estimate of $41.14 million. Lannett Co.’s revenue was up 29.8% compared to the same quarter last year. Analysts expect that Lannett Co. will post $1.48 EPS for the current fiscal year.
Lannett Company, Inc is engaged in developing, manufacturing, marketing and distributing generic versions of branded pharmaceutical products.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.